Edition:
United Kingdom

Sosei Group Corp (4565.T)

4565.T on Tokyo Stock Exchange

11,940JPY
12:17am GMT
Change (% chg)

¥-250 (-2.05%)
Prev Close
¥12,190
Open
¥11,980
Day's High
¥12,130
Day's Low
¥11,880
Volume
107,600
Avg. Vol
432,055
52-wk High
¥15,530
52-wk Low
¥8,590

Latest Key Developments (Source: Significant Developments)

Sosei Group to issue 2.1 mln new shares
Friday, 10 Nov 2017 

Nov 10(Reuters) - Sosei Group Corp <4565.T>:Says it plans to issue 2.1 million new shares through overseas offering .Proceeds to be mainly used for drug discovery and research and development related fund .  Full Article

Sosei Group to advance clinical development in Japan of HTL0018318 in patients with Dementia with Lewy Bodies (DLB)
Thursday, 9 Nov 2017 

Nov 9(Reuters) - Sosei Group Corp <4565.T>:Says it gains a licence to develop and commercialise HTL0018318, a novel muscarinic M1 receptor agonist, in Japan as a potential new treatment for patients with dementia with Lewy bodies (DLB).Says it will undertake a Phase 2 proof-of-concept monotherapy study, expected to begin in Japan in 2018 .  Full Article

Mina Therapeutics partners with Boehringer Ingelheim
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Sosei Group Corp <4565.T>:Strategic minority investment company Mina Therapeutics enters into collaboration and licensing agreement with Boehringer Ingelheim.Under agreement, Mina to receive an upfront payment, funding and payments of up to EUR 307 million​.Mina is also entitled to double-digit royalties on sales of selected products resulting from partnership​.No further financial details were disclosed​.  Full Article

Sosei Group says completion of Japanese Phase III clinical study of SO-1105 for oropharyngeal candidiasis
Monday, 29 Aug 2016 

Sosei Group <4565.T>: Says its Japanese subsidiary Sosei Co. Ltd. has completed the Japanese Phase III study of SO-1105 (miconazole 50 mg, muco-adhesive tablet) for the treatment of oropharyngeal candidiasis; meeting the primary endpoint as requested for submission . Says the study was an open-label, randomized, multi-site, parallel-group, comparative clinical study to investigate the efficacy and safety of SO-1105 in comparison with a commercialized formulation of miconazole in patients with oropharyngeal candidiasis in Japan .Says the cure rate after the completion of the targeted study medication period with SO-1105 was the same as the comparator in terms of the primary endpoint.  Full Article

Sosei Group says $10 million milestone payment from Astrazeneca to Heptares
Wednesday, 6 Jul 2016 

Sosei Group Corp <4565.T>:Says Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, reported that it has been notified by its partner AstraZeneca that the first subject has been dosed with immuno-oncology candidate HTL1071 (AZD4635) in a Phase 1 clinical study, triggering a US$10 million payment from AstraZeneca.  Full Article

Sosei Group says appoints Peter Bains as CEO
Friday, 24 Jun 2016 

Sosei Group : Shinichi tamura, sosei founder and group chairman, president, ceo, appointed as representative executive officer and executive chairman .Sosei appoints Peter Bains as CEO.  Full Article

Sosei Group appoints Peter Bains as CEO
Friday, 24 Jun 2016 

Sosei Group Corp <4565.T>:Says the co appointed Peter Bains as CEO, effective June 24.  Full Article

Sosei Group's unit announces joint research with Kymab Limited
Monday, 18 Apr 2016 

Sosei Group Corp:Says its unit Heptares Therapeutics forms alliance with a bio-medical firm Kymab Limited, on joint research and commercialization of new antibody drugs in cancer immunotherapy therapy area.  Full Article

Sosei Group lowers consolidated full-year outlook for FY 2016
Thursday, 7 Apr 2016 

Sosei Group Corp:Says the company lowered the consolidated full-year outlook for revenue to 8,228 mln yen from 11,732 mln yen for the fiscal year ended March 31, 2016.Sees a decrease of operating profit forecast to 1,130 mln yen from 5,899 mln yen.Sees a decrease of ordinary profit forecast to a loss of 3,331 mln yen from 5,915 mln yen.Sees a decrease of net profit forecast to a loss of 3,444 mln yen from 6,047 mln yen.Sees a decrease of earnings per share to a loss of 225.06 yen from 439.02 yen.Comments the lower sales than expected, increased amortization expenses for intangible assets are the main reasons for the forecast.  Full Article

Sosei Group announces officer changes
Tuesday, 22 Mar 2016 

Sosei Group Corp:Says planned to appoint Peter Bains as president CEO to succeed Shinichi Tamura.Says planned to appoint Shinichi Tamura as chairman.Planned effective in June.  Full Article

BRIEF-Sosei Group to issue 2.1 mln new shares

* Says it plans to issue 2.1 million new shares through overseas offering